E.U. Trumps FDA In Approval Of Biologics

Law360, New York (February 1, 2006, 12:00 AM EST) -- In a sign the United States and the European Union will soon be on different playing fields when it comes to generic biotechnology drugs, the European Commission has moved to grant Sandoz GmbH authority to sell human growth hormone Omnitrope, the first approved “biologic.”

The European Medicines Agency (EMEA) said biologics may now be authorized on the basis of appropriate non-clinical and clinical data requirements. That’s the same basis for approval Sandoz has sought in the United States, using provision 505(b) of the 1984 Hatch Waxman...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.